Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 GlobeNewswire January 05, 2026 – Conference Call and Live Webcast at 8AM ET – NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) (“Bright […]

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire January 05, 2026 SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company

Glacier Bancorp, Inc. Announces Fourth Quarter Earnings Release and Conference Call GlobeNewswire January 05, 2026 KALISPELL, Mont., Jan. 05, 2026 (GLOBE NEWSWIRE) — Glacier Bancorp, Inc. (NYSE: GBCI) will report fourth quarter financial results after the market closes on January 22, 2026. A conference call for investors is scheduled for 11:00 a.m. Eastern Time on

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 05, 2026 TEL AVIV, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13,

Fitell Corporation Announces Share Consolidation GlobeNewswire January 05, 2026 TAREN POINT, Australia, Jan. 05, 2026 (GLOBE NEWSWIRE) — Fitell Corporation (Nasdaq: FTEL) (the “Company”), today announced that it will effect a share consolidation of (i) its outstanding Class A ordinary shares, par value of $0.0016 per share, at a ratio of 1-for-8, with a post-share

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire January 05, 2026 BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to two new employees under the Company's 2025 Inducement Plan

Ingersoll Rand Expands Life Sciences Capabilities with Acquisition of Scinomix, Inc. GlobeNewswire January 05, 2026 Bolt-on acquisition supports the company's growth strategy with scalable opportunities for innovation and market expansion within life sciences Enables Ingersoll Rand to provide more comprehensive solutions using technologies that help streamline workflows with greater automation and increased accuracy for customers

(TSX-V – NEX Board:REVX),(OTC US:REVFF),(OtherOTC:REVFF), VANCOUVER, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) — REV Exploration Corp. (“REV” or the “Company“) (TSXV: REVX; OTC: REVFF) is pleased to announce that, due to strong investor demand, it has upsized the listed issuer financing exemption offering previously announced on December 30, 2025 (the “LIFE Offering”) by $300,000,

REV Exploration Announces Upsizing of Life Offering GlobeNewswire January 05, 2026 VANCOUVER, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) — REV Exploration Corp. (“REV” or the “Company“) (TSXV: REVX; OTC: REVFF) is pleased to announce that, due to strong investor demand, it has upsized the listed issuer financing exemption offering previously announced on December 30,

NEW YORK, NY / ACCESS Newswire / January 5, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Bgin Blockchain Limited ("Bgin" or the "Company") (NASDAQ:BGIN).��Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com�or 646-581-9980, ext.�7980. The investigation concerns whether Bgin and certain of its officers and/or directors have engaged in